P683: A FIRST-IN-HUMAN PHASE 1 STUDY OF ORAL LOXO-338, A SELECTIVE BCL2 INHIBITOR, IN PATIENTS WITH ADVANCED HEMATOLOGIC MALIGNANCIES (TRIAL IN PROGRESS)

Bibliographic Details
Main Authors: W. Jurczak, A. J. Alencar, G. S. Guru Murthy, M. Hoffmann, J. M. Pagel, V. Patel, J. M. Pauff, P. L. Zinzani, S. Le Gouill, A. R. Mato, L. E. Roeker
Format: Article
Language:English
Published: Wiley 2022-06-01
Series:HemaSphere
Online Access:http://journals.lww.com/10.1097/01.HS9.0000845616.77820.49